Table 23.
Occurrence of resistance (%) to selected antimicrobials in Salmonella spp. from laying hen flocks, using harmonised ECOFFs, 22 EU MSs, 2016
| Country | N | GEN | CHL | AMP | CTX | CAZ | MEM | TGC | NAL | CIP | AZM | COL | SMX | TMP | TET |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Austria | 46 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.5 | 6.5 | 0 | 0 | 4.3 | 0 | 13 |
| Belgium | 39 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bulgaria | 11 | 0 | 0 | 18.2 | 0 | 0 | 0 | 0 | 90.9 | 90.9 | 0 | 0 | 36.4 | 18.2 | 9.1 |
| Croatia | 44 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18.2 | 18.2 | 0 | 0 | 0 | 0 | 0 |
| Cyprus | 10 | 20 | 0 | 10 | 0 | 0 | 0 | 0 | 20 | 20 | 0 | 0 | 20 | 10 | 10 |
| Czech Republica | 9 | 0 | 0 | 11.1 | 0 | 0 | 0 | 0 | 11.1 | 11.1 | 0 | 0 | 11.1 | 0 | 11.1 |
| Denmarka | 3 | 0 | 0 | 66.7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 33.3 | 66.7 | 0 | 66.7 |
| Estoniaa | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 33.3 | 33.3 | 0 | 0 | 0 | 0 | 0 |
| France | 92 | 0 | 0 | 4.3 | 0 | 0 | 0 | 0 | 1.1 | 1.1 | 0 | 1.1 | 4.3 | 1.1 | 9.8 |
| Germany | 95 | 1.1 | 2.1 | 7.4 | 0 | 0 | 0 | 0 | 7.4 | 7.4 | 0 | 31.6 | 10.5 | 0 | 7.4 |
| Greece | 59 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.5 | 11.9 | 1.7 | 3.4 | 6.8 | 0 | 5.1 |
| Hungary | 91 | 2.2 | 0 | 6.6 | 0 | 0 | 0 | 1.1 | 17.6 | 22 | 2.2 | 6.6 | 8.8 | 0 | 11 |
| Irelanda | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Italy | 125 | 0 | 4 | 6.4 | 0 | 0 | 0 | 0 | 48.8 | 49.6 | 0 | 7.2 | 14.4 | 6.4 | 12.8 |
| Latviaa | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 0 | 0 | 0 |
| Malta | 52 | 1.9 | 0 | 3.8 | 1.9 | 0 | 0 | 0 | 3.8 | 3.8 | 0 | 0 | 53.8 | 13.5 | 3.8 |
| Poland | 213 | 0 | 0 | 0.5 | 0 | 0 | 0 | 0 | 14.6 | 14.6 | 0 | 3.8 | 6.6 | 0.5 | 5.2 |
| Portugal | 74 | 2.7 | 0 | 1.4 | 0 | 0 | 0 | 0 | 9.5 | 12.2 | 1.4 | 2.7 | 1.4 | 0 | 0 |
| Romania | 36 | 0 | 0 | 2.8 | 0 | 0 | 0 | 0 | 30.6 | 33.3 | 0 | 0 | 8.3 | 0 | 8.3 |
| Sloveniaa | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12.5 | 12.5 | 0 | 0 | 12.5 | 0 | 12.5 |
| Spain | 169 | 0.6 | 1.8 | 7.1 | 0 | 0 | 0 | 1.2 | 15.4 | 17.8 | 0 | 5.3 | 5.9 | 2.4 | 14.8 |
| United Kingdom | 34 | 0 | 0 | 5.9 | 0 | 0 | 0 | 0 | 2.9 | 8.8 | 0 | 0 | 11.8 | 2.9 | 5.9 |
| Total (22 MSs) | 1216 | 0.7 | 0.8 | 4.1 | 0.1 | 0 | 0 | 0.2 | 16 | 17.3 | 0.3 | 5.8 | 9.5 | 2.1 | 8.2 |
| Norwaya | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ECOFFs: epidemiological cut‐off values; EUCAST: European Committee on Antimicrobial Susceptibility Testing; N: number of isolates tested; MSs: Member States; GEN: gentamicin; CHL: chloramphenicol; AMP: ampicillin; CTX: cefotaxime; CAZ: Ceftazidime; MEM: meropenem; TGC: tigecycline, NAL: nalidixic acid; CIP: ciprofloxacin; AZM: azithromycin; COL: colistin; SMX: sulfamethoxazole; TMP: trimethoprim; TET: tetracycline.
a
The occurrence of resistance is assessed on less than 10 isolates and should only be considered as part of the total from all MSs data.